Oncotarget

Research Papers:

Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss

Rafaela Andrade-Vieira, Donna Goguen, Heidi A. Bentley, Chris V. Bowen and Paola A. Marignani _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:12738-12752. https://doi.org/10.18632/oncotarget.2818

Metrics: PDF 1307 views  |   HTML 1714 views  |   ?  


Abstract

Rafaela Andrade-Vieira1, Donna Goguen1, Heidi A. Bentley1, Chris V. Bowen2 and Paola A. Marignani1

1 Department of Biochemistry and Molecular Biology, Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia Canada

2 Department of Radiology, Halifax, Nova Scotia Canada

Correspondence:

Paola A. Marignani, email:

Keywords: LKB1, HER2, pre-clinical, cancer, metabolism

Received: October 20, 2014 Accepted: November 24, 2014 Published: November 25, 2014

Abstract

Cancer therapies that simultaneously target activated mammalian target of rapamycin (mTOR) and cell metabolism are urgently needed. The goal of our study was to identify therapies that effectively inhibited both mTOR activity and cancer cell metabolism in primary tumors in vivo. Using our mouse model of spontaneous breast cancer promoted by loss of LKB1 expression in an ErbB2 activated model; referred to as LKB1-/-NIC mice, we evaluated the effect of novel therapies in vivo on primary tumors. Treatment of LKB1-/-NIC mice with AZD8055 and 2-DG mono-therapies significantly reduced mammary gland tumorigenesis by inhibiting mTOR pathways and glycolytic metabolism; however simultaneous inhibition of these pathways with AZD8055/2-DG combination was significantly more effective at reducing tumor volume and burden. At the molecular level, combination treatment inhibited mTORC1/mTORC2 activity, selectively inhibited mitochondria function and blocked MAPK pro-survival signaling responsible for the ERK-p90RSK feedback loop. Our findings suggest that loss of LKB1 expression be considered a marker for metabolic dysfunction given its role in regulating AMPK and mTOR function. Finally, the outcome of our pre-clinical study confirms therapies that simultaneously target mTORC1/mTORC2 and glycolytic metabolism in cancer produce the best therapeutic outcome for the treatment of patients harboring metabolically active HER2 positive breast cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2818